IRIS UniCatt

Autore, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.060
AS - Asia 3.568
EU - Europa 2.590
SA - Sud America 798
AF - Africa 106
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 2
Totale 11.132
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.952
SG - Singapore 1.567
CN - Cina 905
BR - Brasile 635
IT - Italia 590
SE - Svezia 492
VN - Vietnam 364
DE - Germania 333
FR - Francia 318
GB - Regno Unito 160
IE - Irlanda 150
IN - India 142
FI - Finlandia 122
ID - Indonesia 118
UA - Ucraina 102
JP - Giappone 94
RU - Federazione Russa 92
BD - Bangladesh 83
PL - Polonia 69
AR - Argentina 65
CA - Canada 50
HK - Hong Kong 46
TR - Turchia 43
IQ - Iraq 39
MX - Messico 38
KR - Corea 35
EC - Ecuador 31
CI - Costa d'Avorio 26
AT - Austria 24
NL - Olanda 24
ZA - Sudafrica 24
ES - Italia 20
CO - Colombia 19
BE - Belgio 18
CZ - Repubblica Ceca 16
SA - Arabia Saudita 15
MA - Marocco 13
PY - Paraguay 13
PK - Pakistan 12
UZ - Uzbekistan 12
VE - Venezuela 12
CL - Cile 11
EG - Egitto 11
IR - Iran 10
IL - Israele 9
CH - Svizzera 8
PH - Filippine 8
TN - Tunisia 8
AE - Emirati Arabi Uniti 7
DZ - Algeria 7
KE - Kenya 7
NP - Nepal 7
GR - Grecia 6
HU - Ungheria 5
JM - Giamaica 5
KZ - Kazakistan 5
AZ - Azerbaigian 4
BA - Bosnia-Erzegovina 4
JO - Giordania 4
KG - Kirghizistan 4
OM - Oman 4
PT - Portogallo 4
RO - Romania 4
UY - Uruguay 4
XK - ???statistics.table.value.countryCode.XK??? 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AL - Albania 3
BB - Barbados 3
BG - Bulgaria 3
BO - Bolivia 3
CY - Cipro 3
KW - Kuwait 3
LB - Libano 3
LK - Sri Lanka 3
LT - Lituania 3
NI - Nicaragua 3
NO - Norvegia 3
PE - Perù 3
QA - Qatar 3
RS - Serbia 3
SN - Senegal 3
AM - Armenia 2
AO - Angola 2
AU - Australia 2
BH - Bahrain 2
DO - Repubblica Dominicana 2
GA - Gabon 2
GY - Guiana 2
HR - Croazia 2
KH - Cambogia 2
LU - Lussemburgo 2
LV - Lettonia 2
MD - Moldavia 2
MR - Mauritania 2
MY - Malesia 2
AF - Afghanistan, Repubblica islamica di 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
BZ - Belize 1
CR - Costa Rica 1
Totale 11.114
Salva come PNG Salva come JPEG
Città #
Singapore 784
Chandler 503
San Jose 416
Ashburn 343
Beijing 220
Rome 156
Dublin 145
Ho Chi Minh City 123
Lauterbourg 106
Los Angeles 105
Jakarta 104
Hefei 98
Hanoi 88
Wilmington 84
New York 83
Jacksonville 81
Tokyo 81
Frankfurt am Main 79
Dearborn 76
Ann Arbor 75
Council Bluffs 75
Florence 75
San Mateo 75
Nanjing 73
Munich 70
Cattolica 69
Hyderabad 69
Lancaster 69
Warsaw 64
Chicago 61
Dallas 61
Boston 60
Milan 58
Princeton 51
Helsinki 48
São Paulo 47
Fairfield 46
Woodbridge 46
The Dalles 44
Hong Kong 40
Marseille 40
Buffalo 39
Moscow 39
Houston 38
Nanchang 37
Seattle 37
Boardman 32
Seoul 32
Brooklyn 28
Bremen 27
Santa Clara 27
Abidjan 26
Kent 26
Lappeenranta 25
Lawrence 25
Redwood City 25
Tukwila 25
Paris 24
Turku 24
Kunming 22
Atlanta 21
Cambridge 21
Rio de Janeiro 21
Stockholm 21
Naples 20
Orem 20
Izmir 19
Nuremberg 19
Shanghai 19
Tianjin 19
Brussels 18
Auburn Hills 17
Redmond 17
St Louis 17
Da Nang 16
Washington 16
London 15
Phoenix 15
Pune 15
Shenyang 15
Johannesburg 14
Salt Lake City 14
Campinas 13
Elk Grove Village 13
Guangzhou 13
Hangzhou 13
Tampa 13
Toronto 13
Baghdad 12
Düsseldorf 12
Haiphong 12
Montreal 12
Norwalk 12
Porto Alegre 12
Tashkent 12
Vienna 12
Denver 11
Hải Dương 11
Manchester 11
Mountain View 11
Totale 6.156
Salva come PNG Salva come JPEG
Nome #
Elevated lactate dehydrogenase has prognostic relevance in treatment-naïve patients affected by chronic lymphocytic leukemia with trisomy 12 332
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 179
Role of microRNAs in Chronic Lymphocytic Leukemia 159
EXTREME THROMBOCYTOSIS IN CHRONIC MYELOID LEUKEMIA IN THE ERA OF TYROSINE KINASE INHIBITORS 158
revalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience. 152
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 151
Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia 148
Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma. 146
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: Correlation with biologically-based risk stratification 142
Prevalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience 141
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T 138
High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia 132
Chronic Lymphocytic Leukaemia: Census of Patients Treated in Italian Haematology Units 129
Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia. 127
Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid-19 pandemics 125
Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease 123
What Does Atypical Chronic Lymphocytic Leukemia Really Mean? A Retrospective Morphological and Immunophenotypic Study 122
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells 122
Massive Pulmonary Embolism at the Onset of Acute Promyelocytic Leukemia 122
Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid 121
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. 120
Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia 119
What is the best treatment strategy before autologous peripheral blood stem cell transplantation in POEMS syndrome? 119
Unrelated cord blood transplantation and post-transplant cyclophosphamide 115
COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: what is the role of anti-CD20 antibody? 115
Coagulopathy in Patients with Low/Intermediate Risk Acute Promyelocytic Leukemia treated with First Line Arsenic Trioxide in Combination with All-Trans Retinoic Acid: A Monocentric Experience 114
Massive Pulmonary Embolism at the Onset of Acute Promyelocytic Leukemia 113
Massive Pulmonary Embolism at the Onset of Acute Promyelocytic Leukemia 113
Peripheral Blood Hemopoietic Stem Cell Mobilization Regimens in POEMS Syndrome: A Retrospective Study at 2 Hematologic Italian Centers 113
Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience 113
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments. 112
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study 112
Effect of HLA mismatch on post-transplant infections in allogeneic hematopoietic stem cell transplantation with PTCy-based GvHD prophylaxis 111
the concomitance of lymphoma and breast carcinoma in the bone 111
Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study 109
Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL 108
Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real-life experience 107
Chlorambucil PLUS Rituximab As FRONT-LINE THERAPY in Elderly or Unfit Patients Affected by B-CELL Chronic Lymphocytic Leukemia: Results of A Single-Centre Retrospective Analysis 107
Second haploidentical stem cell transplantation for primary graft failure 107
HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis. 103
Remission of acquired von Willebrand syndrome in a patient with chronic lymphocytic leukemia treated with venetoclax 103
Implications of Genetic, Biological and Clinical Parameters in Patients With Richter Syndrome: A Monocentric Experience 102
Richter transformation in Chronic Lymphocytic Leukemia 102
Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia 102
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience 102
Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region 102
Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants. 102
Safety and efficacy of SARS-Cov2 neutralizing monoclonal antibodies after stem cell transplant or CAR-T cell infusion 101
PlentiPlex™ MYD88 Waldenström lymphoma qPCR assay: A highly sensitive method for detection of MYD88 L265P mutation 101
Treatment options for elderly/unfit patients with chronic lymphocytic leukemia in the era of targeted drugs: A comprehensive review 100
Chronic Lymphocitic Leukaemia: Census of Patients Treated in Italian Haematology Units 97
New developments in the management of chronic lymphocytic leukemia: role of ofatumumab 97
Genetic dynamics in untreated CLL patients with either stable or progressive disease: A longitudinal study 97
Prevalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience 96
Massive Pulmonary Embolism at the Onset of Acute Promyelocytic Leukemia 96
Ibrutinib does not affect ristocetin-induced platelet aggregation evaluated by light transmission aggregometry in chronic lymphocytic leukemia patients 96
Unrelated cord blood transplantation and post-transplant cyclophosphamide 96
Treatment Sequencing in Chronic Lymphocytic Leukemia in 2024: Where We Are and Where We Are Headed 95
Coagulopathy in Patients with Low/Intermediate Risk Acute Promyelocytic Leukemia treated with First Line Arsenic Trioxide in Combination with All-Trans Retinoic Acid: A Monocentric Experience 95
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience 95
Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas 93
Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors 93
Clinical and molecular features of familial chronic lymphocytic leukemia: a pilot monocentric study 92
The concomitance of lymphoma and breast carcinoma in the bone 92
Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T‐cells (CAR‐T): A comprehensive review on incidence, risk factors and current management 91
Days alive outside hospital and readmissions in patients undergoing allogeneic transplants from identical siblings or alternative donors 91
Clinical and molecular features of familial chronic lymphocytic leukemia: a pilot monocentric study 90
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 90
Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory b-precursor acute lymphoblastic leukaemia: Case reports and literature review 90
Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience 89
VEGF and IL-6 Correlation in POEMS: A Potential Upcoming Marker of Active Disease and Early Autologous BMT Response 89
Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia 88
Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors 88
Autologous peripheral blood stem cell transplantation and the role of lenalidomide in patients affected by poems syndrome 87
Autoimmune hemolytic anemia in chronic lymphocytic leukemia: A comprehensive review 86
Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors 85
First-line treatment of Waldenström's macroglobulinemia in Italy: A multicenter real-life study on 547 patients to evaluate the long-term efficacy and tolerability of different chemoimmunotherapy strategies 85
Relapsed/refractory pure red cell aplasia in chronic lymphocytic leukemia successfully treated with acalabrutinib: a case report and review of the literature 85
Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL. 84
Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation 84
Second haploidentical stem cell transplantation for primary graft failure 83
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study 82
Purging with chlorambucil to prevent infusion-related reaction before obinutuzumab administration: A monocentric pilot experience 82
A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia 81
Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease. 80
Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review 80
Enhanced expression of mir-181b in b cells of cll improves the anti-tumor cytotoxic t cell response 80
Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience 79
Treatment Sequencing and Outcome of Chronic Lymphocytic Leukemia Patients Treated at Fondazione Policlinico Universitario Agostino Gemelli IRCCS: A Thirty-Year Single-Center Experience 79
Non-overt disseminated intravascular coagulopathy associated with the first obinutuzumab administration in patients with chronic lymphocytic leukemia 78
New developments in the management of chronic lymphocytic leukemia: role of ofatumumab 76
Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience 76
CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia 76
Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience 75
Chronic Lymphocytic Leukaemia: Census of Patients Treated in Italian Haematology Units 75
Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia 75
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study 74
HNRNPL Restrains miR-155 Targeting of BUB1 to Stabilize Aberrant Karyotypes of Transformed Cells in Chronic Lymphocytic Leukemia 74
VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation 71
Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience 71
Totale 10.506
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.711
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.711
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202113 0 0 0 0 0 0 0 0 0 0 0 13
2021/2022589 51 15 22 24 50 5 7 88 31 33 135 128
2022/20231.442 199 187 106 199 103 193 80 91 165 34 64 21
2023/2024892 39 221 65 77 38 133 65 22 16 34 82 100
2024/20252.000 51 61 135 70 148 60 67 74 226 214 547 347
2025/20264.814 704 190 344 634 725 253 692 271 325 372 181 123
Totale 11.345